Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCD | O00767 | 7/20 | 1.00 |
| ▸ | NPC1 | O15118 | 4/20 | 0.83 |
| ▸ | RAB9A | P51151 | 4/20 | 0.83 |
| ▸ | MEN1 | O00255 | 3/20 | 0.83 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.83 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.83 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.75 |
| ▸ | HTT | P42858 | 2/20 | 0.75 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.75 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.75 |
| ▸ | RELA | Q04206 | 1/20 | 0.75 |
| ▸ | MMP13 | P45452 | 1/20 | 0.68 |
| ▸ | TOP1 | P11387 | 2/20 | 0.67 |
| ▸ | CASP3 | P42574 | 1/20 | 0.65 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.65 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.65 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.65 |
| ▸ | LRRK2 | Q5S007 | 2/20 | 0.62 |
| ▸ | CSNK1D | P48730 | 1/20 | 0.62 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3053529 | 0.91 | NPC1 (1.00) | SCDNPC1RAB9AMEN1KMT2A | |
| SCHEMBL16562172 | 0.90 | NPC1 (0.86) | SCDNPC1RAB9AMEN1KMT2A | |
| SCHEMBL17916702 | 0.89 | SCD (1.00) | SCDNPC1RAB9AMEN1KMT2A | |
| SCHEMBL2754053 | 0.87 | SCD (0.93) | SCDNPC1RAB9AMEN1KMT2A | |
| SCHEMBL19464549 | 0.86 | NPC1 (0.79) | SCDNPC1RAB9AMEN1KMT2A | |
| SCHEMBL16562119 | 0.86 | NPC1 (0.80) | SCDNPC1RAB9AMEN1KMT2A | |
| SCHEMBL4910843 | 0.86 | NPC1 (0.78) | SCDNPC1RAB9AMEN1KMT2A | |
| SCHEMBL4920257 | 0.86 | NPC1 (0.78) | SCDNPC1RAB9AMEN1KMT2A | |
| SCHEMBL30553332 | 0.86 | NPC1 (0.78) | SCDNPC1RAB9AMEN1KMT2A | |
| SCHEMBL4917567 | 0.86 | NPC1 (1.00) | SCDNPC1RAB9AMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2004078115-A2 | BENZOTHIAZOLE COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATMENT AND PROPHYLAXIS OF ROTAVIRUS INFECTIONS AND ASSOCIATED DISEASES | VIROPHARMA, INCORPORATED (US) | 2004-09-16 | — | — | WO | claimed |
| US-9789096-B2 | Methods and compositions for selective and targeted cancer therapy | BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2017-10-17 | — | — | US | disclosed |
| US-9789096-B2 | Methods and compositions for selective and targeted cancer therapy | BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2017-10-17 | — | — | US | disclosed |
| US-20160200695-A1 | Methods and Compositions for Selective and Targeted Cancer Therapy | BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2016-07-14 | — | — | US | disclosed |
| US-20160200695-A1 | Methods and Compositions for Selective and Targeted Cancer Therapy | BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2016-07-14 | — | — | US | disclosed |
| WO-2015035051-A1 | METHODS AND COMPOSITIONS FOR SELECTIVE AND TARGETED CANCER THERAPY | BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2015-03-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160200695-A1 | Methods and Compositions for Selective and Targeted Cancer Therapy | NCOA4, SREBF1, ACOX1 | SCD 4/4885NPC1 840/4885RAB9A 4781/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.